C R Bard (NYSE:BCR) Receives Media Impact Rating of 0.32

Headlines about C R Bard (NYSE:BCR) have been trending positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. C R Bard earned a coverage optimism score of 0.32 on Accern’s scale. Accern also assigned press coverage about the medical instruments supplier an impact score of 45.3317861877906 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72. C R Bard has a fifty-two week low of $223.02 and a fifty-two week high of $337.73. The company has a market capitalization of $24,140.00, a price-to-earnings ratio of 43.64, a P/E/G ratio of 2.53 and a beta of 0.52.

C R Bard (NYSE:BCR) last issued its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.96 by $0.06. C R Bard had a net margin of 9.51% and a return on equity of 19.39%. The business had revenue of $989.80 million during the quarter, compared to analysts’ expectations of $990.64 million. During the same period last year, the company posted $2.64 EPS. The company’s revenue was up 5.1% on a year-over-year basis. analysts anticipate that C R Bard will post 11.89 EPS for the current year.

A number of research analysts have issued reports on the stock. Zacks Investment Research raised shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 target price for the company in a report on Tuesday, December 26th. ValuEngine cut shares of C R Bard from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Barclays increased their target price on shares of C R Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a report on Monday, November 6th. Cowen reaffirmed a “hold” rating and issued a $317.00 target price on shares of C R Bard in a report on Friday, November 3rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of C R Bard in a report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $311.43.

In other news, Director David M. Barrett sold 3,344 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $327.31, for a total transaction of $1,094,524.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Timothy P. Collins sold 55,818 shares of C R Bard stock in a transaction that occurred on Thursday, October 12th. The stock was sold at an average price of $322.03, for a total transaction of $17,975,070.54. The disclosure for this sale can be found here. Over the last three months, insiders have sold 185,499 shares of company stock valued at $61,100,088. Corporate insiders own 0.80% of the company’s stock.

WARNING: “C R Bard (NYSE:BCR) Receives Media Impact Rating of 0.32” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://ledgergazette.com/2018/01/11/c-r-bard-bcr-earns-media-impact-rating-of-0-32.html.

About C R Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply